The high incidence of Scottish Crohn's disease (CD) is not explained by the common three NOD2/CARD15 variants. We aimed to identify population-specific NOD2/CARD15 coding variants. A total of 1478 (320 inflammatory bowel disease patients o16 years, 343 adult CD patients, 542 parents and 273 controls). All NOD2/CARD15 exons were sequenced in 24 CD patients. Sequencing identified 18 single-nucleotide polymorphisms (SNPs) including 4 non-synonymous coding SNPs altering the structure of the Leucine-rich region-two were well established (1007-/C and 908G/R). Two other variants, valine955isoleucine (955V/I) and methionine863valine (863M/V), were genotyped in all subjects. 863M/V carriage was not significantly higher in CD patients vs controls (1.35 vs 0.37%, P ¼ 0.27). 955V/I carriage was no higher in CD or ulcerative colitis patients (12.8 and 15.8%, respectively) compared to controls (16.2%). Transmission disequilibrium test analysis was negative. 955V/I carriage was higher in indeterminate colitis patients (n ¼ 29) compared to controls (41.4 vs 16.2%, P ¼ 0.001, OR ¼ 3.6 (1.6-8.2)). Population-specific NOD2/CARD15 exonic variants do not account for the high-CD prevalence in Scotland.
Introduction
The chronic inflammatory bowel diseases (IBDs), Crohn's disease (CD), ulcerative colitis (UC) and indeterminate colitis (IC) are now common causes of morbidity in children in the Western World. 1 Scotland has the highest incidence of paediatric IBD in the United Kingdom, 2 and one of the highest incidence rates of paediatric CD throughout the world. The aetiology of IBD is complex with data supporting a role for a number of environmental agents and genes. [3] [4] [5] The NOD2/CARD15 gene was the first gene described conferring increased susceptibility to CD. 6, 7 Since the two initial studies in 2001, three mutations within the NOD2/ CARD15 gene (a frameshift (1007-/C) and two missense mutations 702R/W and 908G/R) have been associated with increased susceptibility to CD in most Caucasian populations studied. 8 Within Caucasian populations the contribution of these three mutations to disease susceptibility varies markedly with a significantly lower contribution in Northern European [9] [10] [11] [12] [13] [14] [15] compared to Southern European populations. 6, 13, [16] [17] [18] In the era of genome-wide association studies, NOD2/CARD15 has been identified at the genome-wide significance level in most populations studied. 3 The contribution of the three common NOD2/CARD15 mutations to disease susceptibility in the Scottish paediatric population is modest, with a population attributable risk (PAR) lower than in most other populations studied at 8%. 19 In candidate gene studies to date within this population, increased disease susceptibility has been demonstrated for the IBD5 region, the promoter region of the TNFA gene and the DLG5 gene, [20] [21] [22] a protective effect for IL23R 23 but no role for NOD1/CARD4, ATG16L1 or CCL20 gene mutations. [24] [25] [26] [27] The nod2/card15 protein consists of three separate domains: CARDs which are involved in protein-protein interactions, a centrally located nucleotide-binding domain that mediates self-oligomerisation and at the C-terminal the (Leucine-rich region, LRR) domain that is critically important for interacting with luminal bacteria. 28 Muramyl dipeptide, the minimal essential structure of bacterial peptidoglycan carried on bacterial cell walls, is specifically recognised by the LRR domain. 29 Binding of bacteria modifies the inflammatory response within the cell by an effect on nuclear factor-kB activity. 30 Expression of NOD2/CARD15 is found within intestinal epithelial cells with highest concentrations of NOD2/ CARD15 mRNA found in Paneth cells. 31 Mutations within the NOD2/CARD15 gene affect the secretion of defensins by Paneth cells. 32 We sequenced all 12 exons of the NOD2/CARD15 gene in a cohort of 24 CD patients then assessed the contribution of 2 exonic variants affecting the amino acid sequence of the critical LRR protein domain.
Results and discussion
A total of 18 single-nucleotide polymorphisms (SNPs) were identified by sequencing the DNA of 24 patients (Supplementary Table 1 -primer design; Supplementary Table 2 -results). SNPs were then selected for further analysis if these resulted in an amino acid change in the LRR region of the protein. Four SNPs were identified-of these two were the known disease-associated variants 908G/R and 1007-/C. 19 The remaining two (methionine863valine (863M/V) and valine955isoleucine (955V/I)) were subjected to further analysis in 1478 subjects including 663 IBD patients (Supplementary Table 3 ). These two SNPs were not in strong linkage disequilibrium (pair-wise D 0 score 0.34, calculated using Haploview; Figure 1 ). Table 4) 955V/I (rs5743291). There was no significant difference in carriage rates of the 955V/I variant in patients with CD or UC compared to healthy controls (12.8 vs 16.2%, P ¼ 0.20 and 15.8 vs 16.2%, P ¼ 0.86, respectively). The carriage rate of 955V/I variants was significantly higher in patients with IC compared to healthy controls (41.4 vs 16.2%, P ¼ 0.001 OR ¼ 3.65 (1.62-8.21)), but should be interpreted with relative caution given the small numbers in the IC patient group (n ¼ 29). Transmission disequilibrium test (TDT) analysis using family-based association testing, 33 was negative (data available on request). There was no significant difference between carriage of 955V/I variants when stratified for carriage of variants of the common three NOD2/CARD15 mutations (P ¼ 0.45).
Case-control analysis (Supplementary
863M/V. Carriage of 863M/V variants was not significantly different in CD patients compared to healthy controls (1.35 vs 0.37%, P ¼ 0.27). No variants were detected in UC/IC patients.
Regression analysis of CD susceptibility genes in Scottish children
Applying a forward-likelihood ratio stepwise logistic regression model using SPSS v.14, genotypes and/or carriage status of genes previously studied in the Scottish early onset population were analysed; the three common NOD2/CARD15 polymorphisms (702R/W, 908G/R and 1007-/C); þ 32656 26 were assessed for their relative contribution to CD susceptibility in the early onset population. Only NOD2/CARD15 1007-/C contributed significantly to CD susceptibility (P ¼ 0.009, OR 7.71 (1.65-35.98)).
This study demonstrates that there is unlikely to be a major contribution of other coding NOD2/CARD15 variants to CD susceptibility in the Scottish paediatric CD population and by implication therefore in most other Northern European CD populations. This is an important finding given the relatively small contribution of the three common NOD2/CARD15 mutations in the Scottish population that has been demonstrated both in children, 19 and adults with CD. 10 Indeed, it would seem on detailed analysis of the SNPs within the candidate genes studied thus far in the Scottish early-onset population that the only significant contribution to disease susceptibility comes from the NOD2/CARD15 1007-/C mutation. In support of this finding, meta-analysis data from two separate studies demonstrate that the 1007-/C mutation made the most significant contribution to increased disease susceptibility. 8, 34 In addition, our previous work using TDT analysis has demonstrated in the Scottish population that only the 1007-/C mutation is significantly over transmitted from parents to children. 19 In case-control analysis in Scottish adults and children there was significantly higher mutant allele frequency in CD patients of both 1007-/C and 908G/R but no significant difference in 702R/W frequency between cases and controls. 10, 19 This study has further confirmed that there are unlikely to be other NOD2/CARD15 SNPs apart from these two (1007-/C and 908G/R) that significantly contribute to disease susceptibility in our population.
The results from gene sequencing in this current study are similar to those found in previous studies. In the study by Lesage et al. 35 sequencing the NOD2/CARD15 gene in an European population, 9 SNPs had an allele frequency of 45% in the CD group, all of which were identified in the present study (SNPs 3, 4, 6, 7, 8 and 14 listed in Supplementary Table 2) plus the three common NOD2/CARD15 mutations. The replication of data from the Lesage study helps validate the findings of the current study. It suggests that the techniques used were appropriate to identify any common NOD2/CARD15 variant that may have been present in the Scottish population.
As part of the sequencing study performed by Lesage et al., both of the SNPs subject to detailed analysis within this present study were identified. The allele frequency of the 955V/I mutation was lower in CD patients than controls (63/906 (7.0%) vs 21/206 (10.2%), P ¼ 0.11) and comparative figures from this present study are remarkably similar (65/1012 (6.4%) vs 43/506 (8.5%), P ¼ 0.14). The allele frequency of the 863M/V allele was rare in the Lesage et al. study and it was found in 4/906 (0.4%) alleles compared to 7/1040 (0.6%) in the current study. The SNP was not found in any UC patients in either study and was found in only one healthy control in the Scottish study.
In this study we only analysed in further detail SNPs causing amino acid changes within the LRR region of the nod2/card15 protein. We concentrated on this area because previous work has demonstrated the majority of CD-associated SNPs lie within this region, for example of the 31 potential disease causing mutations identified by Lesage et al. 35 93% were coding for amino acid changes in the LRR region. The LRR is the key component of the innate immune system with response to a number of microbial pathogens and defects in LRR signalling have been demonstrated in a number of inflammatory diseases including CD. 36 In addition, splice variants of NOD2/CARD15 have been found to reduce the size of the LRR leading to lack of ligand sensing. 37 One of the strengths of the current study is that it is one of very few that has studied candidate genes in patients with IC, with most other groups choosing to exclude such patients. Paediatric IBD populations may be particularly appropriate to study these patients, as proportionately they contain a larger number of IC patients (up to 30% of total IBD cases) compared to published adult series. 2, 38 The research focus thus far in IC patients has been limited to the study of serological rather than genetic markers. 39, 40 This is the first study to demonstrate a higher carriage of any NOD2/CARD15 mutation in patients with IC, although we recognise that the number of patients analysed is small (n ¼ 29) and the result may therefore be a false-positive. It would be interesting to see if the finding could be replicated by other groups.
It is intriguing, and indeed may seem superficially paradoxical, that the countries of Northern Europe where the incidence of CD and IBD are highest, [41] [42] [43] [44] have the lowest carriage of the commonest pre-disposing mutations identified thus far. The PAR relating to the common three NOD2/CARD15 mutations in Northern Europe is significantly lower than Southern Europe. 4 This study demonstrates that there are no other mutations within the gene that account for this low PAR in the Scottish population, replicating the data from Medici et al. 45 in a Norwegian population. The identification of a common 'Northern European' susceptibility gene remains to be explored. We have examined two other candidate genes in the Scottish and Swedish populations (IBD5 and NOD1/CARD4) and have demonstrated no/minor contributions to disease susceptibility. 20, 26, 46 In conclusion, we have not identified any populationspecific mutations that explain the high rates of CD in Scotland, despite sequencing all exons and exon-intron boundaries of the NOD2/CARD15 gene. The lack of genome-wide analysis in Northern European populations (with the exception of a small UC-dominated Finnish genome-wide scan) 47 means at present the major genetic determinants of disease susceptibility of the Scottish population and indeed other Northern European populations remain to be answered. 
